US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER

SYDNEY, July 6, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased...

Related Keywords

Australia ,United States ,Sydney ,New South Wales ,American ,Jeffrey Rubens ,Genentech ,Drug Administration ,American Association Of Cancer Research ,Oncology Consortium ,St Jude Children Research Hospital In Memphis ,Kazia Therapeutics Limited ,Drug Administration Safety ,Kazia Therapeutics ,United States Food ,Rare Pediatric Disease Designation ,Pediatric Disease Designation ,Professor Jeffrey Rubens ,American Association ,Cancer Research ,Annual Meeting ,New Orleans ,Innovation Act ,Rare Pediatric Disease Priority Review Voucher ,Pacific Pediatric Neuro Oncology Consortium ,Research Hospital ,Therapeutics Limited ,Orphan Drug Designation ,Fast Track Designation ,Orphan Designation ,